Roberto Ravasio

768 total citations
99 papers, 413 citations indexed

About

Roberto Ravasio is a scholar working on Economics and Econometrics, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roberto Ravasio has authored 99 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Economics and Econometrics, 23 papers in Immunology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roberto Ravasio's work include Health Systems, Economic Evaluations, Quality of Life (18 papers), Biosimilars and Bioanalytical Methods (16 papers) and Pharmaceutical Economics and Policy (10 papers). Roberto Ravasio is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (18 papers), Biosimilars and Bioanalytical Methods (16 papers) and Pharmaceutical Economics and Policy (10 papers). Roberto Ravasio collaborates with scholars based in Italy, Netherlands and United States. Roberto Ravasio's co-authors include Rino Micheloni, Alessia Marelli, Carlo Lucioni, G Chirico, Felicetto Ferrara, Giovanni Di Minno, Mario Guidotti, Roberto Sabbatini, Eugenio Aguglia and Alberto Batticciotto and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Proceedings of the IEEE.

In The Last Decade

Roberto Ravasio

80 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberto Ravasio Italy 12 83 71 66 63 47 99 413
Κωνσταντίνος Λαμπρόπουλος Greece 14 146 1.8× 114 1.6× 41 0.6× 38 0.6× 14 0.3× 79 771
Konstantinos Oikonomou Greece 13 28 0.3× 163 2.3× 50 0.8× 12 0.2× 43 0.9× 24 501
Stephen T. Vernon Australia 17 52 0.6× 75 1.1× 11 0.2× 57 0.9× 24 0.5× 41 1.1k
Albert J. Rogers United States 18 170 2.0× 37 0.5× 18 0.3× 9 0.1× 35 0.7× 92 1.2k
Sushil Ghimire United States 13 82 1.0× 36 0.5× 6 0.1× 14 0.2× 69 1.5× 35 615
Abhishek Chauhan United Kingdom 15 39 0.5× 238 3.4× 79 1.2× 2 0.0× 16 0.3× 34 726
Yinan Huang United States 9 23 0.3× 54 0.8× 16 0.2× 11 0.2× 11 0.2× 38 334
James E. Brick United States 14 46 0.6× 130 1.8× 11 0.2× 4 0.1× 174 3.7× 24 567
Hsiao-Han Wang Taiwan 12 50 0.6× 63 0.9× 10 0.2× 4 0.1× 86 1.8× 20 428
Ralph Peeters Netherlands 11 17 0.2× 47 0.7× 8 0.1× 59 0.9× 52 1.1× 23 448

Countries citing papers authored by Roberto Ravasio

Since Specialization
Citations

This map shows the geographic impact of Roberto Ravasio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Ravasio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Ravasio more than expected).

Fields of papers citing papers by Roberto Ravasio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Ravasio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Ravasio. The network helps show where Roberto Ravasio may publish in the future.

Co-authorship network of co-authors of Roberto Ravasio

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Ravasio. A scholar is included among the top collaborators of Roberto Ravasio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Ravasio. Roberto Ravasio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stingeni, Luca, et al.. (2025). Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy. Global & Regional Health Technology Assessment. 12(1). 70–79.
2.
3.
Ravasio, Roberto, et al.. (2023). Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy. SHILAP Revista de lepidopterología. 10. 13–21.
4.
Bertolani, Arianna, et al.. (2022). The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study. SHILAP Revista de lepidopterología. 9. 73–81. 1 indexed citations
5.
Minno, Giovanni Di & Roberto Ravasio. (2021). Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy. SHILAP Revista de lepidopterología. 8. 43–52. 9 indexed citations
6.
Gisondi, Paolo, et al.. (2021). Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. SHILAP Revista de lepidopterología. 8. 120–130. 2 indexed citations
7.
Ravasio, Roberto, Roberto Giacomelli, & Stefano Bianchi. (2020). Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease. SHILAP Revista de lepidopterología. 7(1). 72–80. 2 indexed citations
8.
Ravasio, Roberto, Giampiero Girolomoni, & Roberto Gorla. (2018). Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. Global & Regional Health Technology Assessment. 5(1). 1 indexed citations
9.
Mazzi, S., Roberto Ravasio, Gabriele Forlani, et al.. (2017). Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. ClinicoEconomics and Outcomes Research. Volume 9. 711–720. 4 indexed citations
10.
Petrosillo, Nicola & Roberto Ravasio. (2017). The cost of Clostridium difficile infection (CDI) in hospital in Italy. Global & Regional Health Technology Assessment. 4(1). 77–83. 1 indexed citations
11.
Ravasio, Roberto. (2016). Cost-Effectiveness Analysis of Triptorelin versus Leuprolide in the Treatment of Advanced Prostate Cancer. Global & Regional Health Technology Assessment. 3(3). 150–154. 1 indexed citations
12.
Ravasio, Roberto, et al.. (2016). Economic Evaluation of Nevirapine plus Raltegravir as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1 Infected Patients. Global & Regional Health Technology Assessment. 3(2). 110–114. 1 indexed citations
13.
14.
Batticciotto, Alberto, Roberto Ravasio, Marta Riva, & Piercarlo Sarzi‐Puttini. (2016). Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. Advances in Therapy. 33(8). 1360–1373. 12 indexed citations
15.
Bartolomei, Luigi, Anna Rita Bentivoglio, Marco Frontoni, et al.. (2016). Cost Minimization Analysis of Bont-As in the Treatment of Upper Limb Spasticity and Cervical Dystonia. Global & Regional Health Technology Assessment. 3(1). 23–31. 1 indexed citations
16.
Fagiuoli, S., Roberto Ravasio, Maria Grazia Lucà, et al.. (2015). Management of hepatitis C infection before and after liver transplantation. World Journal of Gastroenterology. 21(15). 4447–4456. 13 indexed citations
17.
Ravasio, Roberto, et al.. (2015). Conditional Agreements For Innovative Therapies In Italy: The Case Of Pirfenidone. Value in Health. 18(7). A505–A505. 1 indexed citations
18.
Ravasio, Roberto, Giuseppe Nicolò, & Marco Vaggi. (2014). Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy. Global & Regional Health Technology Assessment. 2(1). GRHTA.5000186–GRHTA.5000186. 2 indexed citations
19.
Ravasio, Roberto, Cinzia Ortega, Roberto Sabbatini, & Camillo Porta. (2011). Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. Clinical Drug Investigation. 31(7). 507–517. 11 indexed citations
20.
Costanzo, Francesco Di, Roberto Ravasio, Alberto Sobrero, et al.. (2008). Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon Cancer. Clinical Drug Investigation. 28(10). 645–655. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Κωνσταντίνος Λαμπρόπουλος Breakdown of academic impact, for papers by Konstantinos Oikonomou Breakdown of academic impact, for papers by Stephen T. Vernon Breakdown of academic impact, for papers by Albert J. Rogers Breakdown of academic impact, for papers by Sushil Ghimire Breakdown of academic impact, for papers by Abhishek Chauhan Breakdown of academic impact, for papers by Yinan Huang Breakdown of academic impact, for papers by James E. Brick Breakdown of academic impact, for papers by Hsiao-Han Wang Breakdown of academic impact, for papers by Ralph Peeters
Rankless by CCL
2026